Tag: Haemodialysis
WAVE trial reports Wrapsody superiority over standard PTA
Six-month results of the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial have reported superior target lesion primary patency (TLPP) with Wrapsody (Merit Medical) cell-impermeable...
Xeltis receives IDE approval from US FDA for haemodialysis vascular access...
Xeltis has announced that it has gained approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) submission to...
WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study completes enrolment
Merit Medical has announced that is has completed enrolment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective,...
Study suggests Black patients more prone to dialysis graft failure
Compared to other races, African American patients are more likely to experience premature arteriovenous (AV) graft failure in the treatment of advanced kidney failure,...
Lydus Medical announces US FDA clearance of microvascular anastomosis aid device
Lydus Medical is pleased to announce that the Vesseal has received US Food and Drug Administration (FDA) 510(k) clearance. The Vesseal is a microvascular...
Vascular Therapies initiates enrolment in ACCESS 2 clinical trial
Vascular Therapies has announced that the first patient in the ACCESS 2 clinical trial was enrolled by Nikhil Kansal at Harbor-UCLA Medical Center in Torrance, USA.
The...
First patient enrolled in Merit Medical’s WRAPSODY registry study
Merit Medical has announced the successful enrolment of the first patient in its WRAP registry study in a press release. This study will evaluate...
VentureMed completes enrolment of Flex Vessel Prep system randomised controlled trial...
VentureMed Group recently announced that it has completed enrolment of a randomised controlled trial (RCT) titled 'Flex Vessel Prep prior to PTA for the...
Bluegrass Vascular announces Medicare decision to assign New Technology Ambulatory Payment...
Bluegrass Vascular Technologies (Bluegrass Vascular) announced today that the Centers for Medicare & Medicaid Services (CMS) has finalised a new Healthcare Common Procedure Coding...
Artio Medical completes enrolment of first-in-human trial investigating Amplifi vein dilation...
Artio Medical announced today it has completed enrolment in its first-in-human study evaluating the Amplifi vein dilation system. In the study, five patients were treated...
Arteriovenous fistulas contribute to higher survival of haemodialysis patients with COVID-19
A new study, published online in The Journal of Vascular Access (JVA), suggests that arteriovenous fistulas (AVFs) contribute to higher survival of haemodialysis patients...
Study supports tunnelled haemodialysis catheter use for permanent dialysis access
In a recent study, Victor Demaerel (University Hospitals Leuven, Leuven, Belgium) and colleagues found that tunnelled haemodialysis catheter (THC) survival in 352 patients was...
Vascular Therapies announces clinical results from phase 3 randomised multicentre clinical...
Vascular Therapies recently announced results from its phase 3 clinical trial in which Sirogen showed encouraging arteriovenous fistula (AVF) outcomes in elderly end-stage renal...
BD announces enrolment in postmarket studies of the WavelinQ endoAVF system
BD announced today that enrolment has begun and the first patients have been treated in the postmarket surveillance study, CONNECT-AV.
CONNECT-AV is a prospective, single-arm,...
Medtronic launches IN.PACT AV DCB in Japan for patients undergoing haemodialysis
Medtronic has announced the launch of IN.PACT AV drug-coated balloon (DCB) in Japan. IN.PACT AV DCB is indicated for the treatment of obstructive lesions...
PatenSee initiates first-in-human trial with its contactless imaging surveillance system for...
PatenSee has initiated a first-in-human clinical trial to assess its machine vision-based surveillance system, a press release from the company reveals. The trial, led...
New standardised reporting system suggests arteriovenous graft infections may be less...
“Using an objective system that discriminates between aetiology and outcome allows a more complete, objective understanding of relative infection risks and outcomes for arteriovenous...
Transit Scientific announces close of its Series A financing round
Transit Scientific has announced the close of its Series A financing round. The round was led by a large multinational investor and joined by...
BIOLUX AV trial demonstrates safety and efficacy of Passeo-18 Lux DCB...
Recent data from the investigator-initiated, randomised controlled trial (RCT), BIOLUX AV, showed that the treatment of patients with dysfunctional haemodialysis access with BIOTRONIK's Passeo-18...
COVID-related hypercoagulability linked to elevated malfunction rate in temporary haemodialysis catheters
Hypercoagulability in COVID-19 patients leads to an increase in the malfunction rate of temporary haemodialysis catheters—but heparin locking of the catheters is linked to...
Risk of ischaemic steal syndrome and patency rate comparable for tapered...
In their recent systematic review and meta-analysis, Venkata Sai Jasty (University of Arizona, Tuscon, USA) and colleagues found that the risk of ischaemic steal...
ISABELLA trial for the treatment of failing AV fistulas in haemodialysis...
MedAlliance has announced completion of patient enrolment in the ISABELLA clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of...
Older age and diabetes mellitus identified as risk factors for poor...
Different risk factors affect patency between vascular access construction and the first percutaneous transluminal angioplasty, Mahoko Yoshida (Hiroshima University Hospital, Hiroshima, Japan) and colleagues...
Artio Medical acquires Flow Forward Medical, expanding peripheral vascular portfolio
Artio Medical today announced it has acquired Flow Forward Medical, a medical device company developing methods for establishing and maintaining vascular access sites.
This...
VasQ external support awarded breakthrough device designation by the FDA
The US Food and Drug Administration (FDA) has designated Laminate Medical’s VasQ external support for the creation of arteriovenous fistulas (AVF) in haemodialysis patients...
Bluegrass Vascular Technologies announces first US commercial cases with the Surfacer...
Bluegrass Vascular Technologies has announced that the first US commercial cases using the Surfacer Inside-Out access catheter system were completed at Santa Clara Valley...
LINC 2020: One year IN.PACT AV results show sustained patency benefit...
NOTE: This video is ONLY available to watch in selected countries and geographies
The one-year IN.PACT AV trial results, first presented at LINC 2020 (28–31 January, Leipzig,...
IVUS during haemodialysis access “aids device selection and adequacy of treatment”
Narayan Karunanithy outlines the benefits of intravascular ultrasound (IVUS) during haemodialysis access intervention.
Thoracic central veins include intra-thoracic segments of the internal jugular, subclavian, brachiocephalic...
A thumbnail sketch of haemodialysis access: Past, present, and future in...
Bart Dolmatch gives an overview of the history of haemodialysis access in the USA, and balances the pros and cons of current access options....
Comparing and contrasting surgically-created AVFs with those made by endovascular means
Nicholas Inston (Birmingham, UK) tells Vascular News at LINC 2019 about the exciting field of percutaneous arteriovenous fistula (AVF) creation, the main devices and...
FDA approves Ellipsys Vascular Access System for non-surgical dialysis fistula creation
Ellipsys Vascular Access System (Avenu Medical) has been granted De Novo marketing authorisation from the Food and Drug Administration (FDA). Ellipsys is a minimally-invasive...
everlinQ endoAVF receives FDA de novo marketing approval
everlinQ endoAVF System (TVA Medical) is now approved by the US Food and Drug Administration for de novo marketing. This innovative, minimally invasive technology...
Humacyte appoints Jeffrey Lawson as president and CEO
Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...
Meta-analysis shows positive experience for patients who received an endovascular arteriovenous...
An international meta-analysis of clinical experience in patients who received an endovascular arteriovenous fistula (endoAVF) for haemodialysis access was presented at Leipzig Interventional Course...
Bluegrass Vascular announces strategic relationship with Merit Medical
Bluegrass Vascular has announced that it is entering into a strategic relationship with Merit Medical. The agreement will streamline European distribution of the recently...
